Lyell Immunopharma (LYEL) Common Equity (2020 - 2026)

Lyell Immunopharma has reported Common Equity for 7 years, with the latest figure at $273.7 million in Q1 2026.

• Quarterly Common Equity fell 18.68% year-over-year to $273.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $273.7 million (down 18.68% YoY) and the FY2025 annual result came in at $248.2 million, down 35.17% from the prior year.
• Common Equity advanced to $273.7 million in Q1 2026 per LYEL's latest filing, from $248.2 million in the prior quarter.
• Over five years, Common Equity peaked at $881.2 million in Q1 2022 and troughed at $248.2 million in Q4 2025.
• A 5-year average of $579.1 million and a median of $603.2 million in 2024 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity jumped 363.81% in 2022, then slumped 47.23% in 2025.
• Over 5 years, Common Equity stood at $833.3 million in 2022, then retreated by 21.4% to $655.0 million in 2023, then slumped by 41.55% to $382.8 million in 2024, then sank by 35.17% to $248.2 million in 2025, then gained by 10.26% to $273.7 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $273.7 million, $248.2 million, and $329.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.